Capricor, Replimune reviews signal FDA’s return to reliability but every application will stand alone

Summary

The article discusses FDA leadership efforts to restore reliability and transparency following former Commissioner Marty Makary's tenure, noting that Capricor and Replimune reviews exemplify this shift while emphasizing that each application will be evaluated independently.